Faron Result of Annual General Meeting

RNS Number : 4092Z

Faron Pharmaceuticals Oy

26 May 2016

 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Result of Annual General Meeting

TURKU - FINLAND 26 May 2016 - Faron Pharmaceuticals Ltd (LON: FARN) is pleased to announce that all resolutions proposed at its Annual General Meeting held today and as set out in the Company's announcement dated 4 May 2016, were duly passed by shareholders.

Commenting on the meeting, Frank Armstrong, Chairman of Faron, said: "We are delighted to have such support from our shareholders at the very first Annual General Meeting as a listed company. We thank our shareholders for sharing Faron´s mission of life-saving drug development. We are looking forward to making further significant progress with our innovations to develop new treatments for true unmet medical needs."

For more information, please contact:

Faron Pharmaceuticals Oy

Katja Wallenlind

Phone [phone]
E-mail: [e-mail]

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson and Rebecca Anderson

Phone: [phone]

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: [phone]

Whitman Howard Limited, Nominated Broker

Ranald McGregor-Smith, Francis North

Phone: [phone]

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: [phone]

E-mail: [e-mail]

 

About Faron Pharmaceuticals Ltd.

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat acute respiratory distress syndrome ("ARDS"), a rare, severe, life threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach called TIET (Tumour Immunity Enabling Technology). Faron Pharmaceuticals Ltd. is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com

 

END

 

 

RAGLIFEAELIRFIR